Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 21;217(11):e20201181. doi: 10.1084/jem.20201181

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Schmidt et al.

This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Figure 4. — Measurement of neutralization activity in COVID-19 convalescent donor plasma. (A) Plasma neutralization of SARS-CoV-2. Serial fivefold dilutions of plasma samples from convalescent donors were incubated with SARS-CoV-2 (n = 3 replicates) and residual infectivity determined using VeroE6 target cells, expressed as percentage of infected cells by immunostaining. (B) Plasma neutralization of HIV-1_NLΔEnv-NanoLuc pseudotyped virus using 293T/ACE2*(B) target cells, rVSVΔG/NG-NanoLuc pseudotyped virus using Huh7.5 target cells, or replication-competent rVSV/SARS-CoV-2/GFP using 293T/ACE2(B) target cells. Residual infectivity was quantified by measuring either NanoLuc luciferase (RLU) or the percentage of GFP-positive cells, as indicated. (C) Correlation between NT₅₀ values for each of the 20 plasmas for each of the surrogate viruses (x axis) and NT₅₀ values for the same plasmas for SARS-CoV-2 (y axis).